Combining PAC-1 and Doxorubicin for Improved Sensitization of Osteosarcoma Cells to Apoptotic Signals
Canine osteosarcoma accounts for approximately 90 percent of primary bone cancers in dogs. Conventional treatment for these dogs consists of limb amputation, followed by chemotherapy, for which doxorubicin is commonly used. This student project will test whether PAC-1, a synthesized chemical compound that induces cell suicide in cancer cells, is able to improve or restore the sensitivity of canine osteosarcoma cells to treatment with conventional anticancer drugs, such as doxorubicin. The student will administer PAC-1 in combination with doxorubicin in vitro using osteosarcoma cells. The data could provide necessary evidence as to whether treatment of osteosarcoma cells with PAC-1 improves treatment.
Julie J. Song, PhD, University of Illinois
Sponsor: Golden Retriever Foundation